Cargando…
Genetically engineered endostatin-lidamycin fusion proteins effectively inhibit tumor growth and metastasis
BACKGROUND: Endostatin (ES) inhibits endothelial cell proliferation, migration, invasion, and tube formation. It also shows antiangiogenesis and antitumor activities in several animal models. Endostatin specifically targets tumor vasculature to block tumor growth. Lidamycin (LDM), which consists of...
Autores principales: | Jiang, Wen-guo, Lu, Xin-an, Shang, Bo-yang, Fu, Yan, Zhang, Sheng-hua, Zhou, Daifu, Li, Liang, Li, Yi, Luo, Yongzhang, Zhen, Yong-su |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4016579/ https://www.ncbi.nlm.nih.gov/pubmed/24128285 http://dx.doi.org/10.1186/1471-2407-13-479 |
Ejemplares similares
-
Tissue factor-targeted lidamycin inhibits growth and metastasis of colon carcinoma
por: ZHANG, QING, et al.
Publicado: (2013) -
Small antibody fusion proteins with complementarity-determining regions and lidamycin for tumor targeting therapy
por: ZHONG, GEN-SHEN, et al.
Publicado: (2013) -
Site-specific PEGylation of lidamycin and its antitumor activity
por: Li, Liang, et al.
Publicado: (2015) -
Comparisons of biophysical properties and bioactivities of mono-PEGylated endostatin and an endostatin analog
por: Wang, Shan, et al.
Publicado: (2016) -
EZH2 mediates lidamycin-induced cellular senescence through regulating p21 expression in human colon cancer cells
por: Sha, Ming-Quan, et al.
Publicado: (2016)